Biotech | May 07, 2022
Gut microbiome as a tool in regenerative medicine
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Recommendation is based on pivotal data from the phase III POLARIX study
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays
Subscribe To Our Newsletter & Stay Updated
